

Announcement



The European Organization for Research and Treatment of Cancer (EORTC) has established an office for the development of new anticancer drugs (NDDO = New Drug Development Office) located at the Free University Hospital, Amsterdam, The Netherlands. The NDDO is coordinating preclinical research and early clinical evaluation of new potential anticancer drugs in cooperation with investigators of many European Cancer Centers. The NDDO is active in the areas of drug acquisition, screening, formulation, toxicology and clinical phase I trials. The present staff of the NDDO consists of a Medicinal Chemist and a Clinical Pharmacologist.

In order to ensure the quality of EORTC phase I studies we have a vacancy for a

clinical monitor (MD)

His/her function will be to develop a monitoring system for EORTC phase I studies to meet requirements of EORTC and national registration authorities. He/she will regularly visit EORTC investigators participating in early clinical studies throughout Europe to discuss the progress of studies along with side effects encountered, to audit patients' case report forms and to monitor the use of investigational drugs. At the Amsterdam office, which coordinates phase I studies, he/she is expected to hold responsibility for the studies and related subjects, while working in a team with the other colleagues.

Candidates with experience in protocol treatment, early clinical studies and monitoring, preferably in the area of oncology, will be considered with priority.

For further information you can contact dr. B. Winograd, telephone 31 20 5485193.

Application with detailed c.v. should be sent to the Personnel Department of VU ziekenhuis, de Boelelaan 1119, 1081 HV Amsterdam, the Netherlands. **Please write reference number C.015.7 on the envelope.**

VU
academisch **ziekenhuis**

Academisch Ziekenhuis Vrije Universiteit